Published in Medical Letter on the CDC and FDA, July 22nd, 2007
Slimmer, known generically as sibutramine mesilate, is an improved version drug which is developed domestically. Han Mi had invested 4.2 billion won in the development of Slimmer for five years with financial supports from the Ministry of Commerce, Industry and Energy.
Slimmer went through preclinical, phase I, phase III trials and toxicity studies almost like a new drug. Han Mi said "Only preclinical and phase I trials are required for an improved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.